This dosage information may not include all the information needed to use Ceftaroline safely and effectively. See additional information for Ceftaroline.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Skin and Structure Infection
600 mg IV, infused over 1 hour, every 12 hours for 5 to 14 days
Usual Adult Dose for Pneumonia
Community acquired: 600 mg IV, infused over 1 hour, every 12 hours for 5 to 7 days
Renal Dose Adjustments
CrCl greater than 30 to less than or equal to 50 mL/min: 400 mg IV, infused over 1 hour, every 12 hours
CrCl 15 to less than or equal to 30 mL/min: 300 mg IV, infused over 1 hour, every 12 hours
End-stage renal disease (CrCl less than 15 mL/min): 200 mg IV, infused over 1 hour, every 12 hours
Liver Dose Adjustments
Data not available
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterials. Anaphylaxis and anaphylactoid reactions have been reported with ceftaroline. The drug should be discontinued if an allergic reaction occurs. Serious acute hypersensitivity (anaphylactic) reactions may require treatment with epinephrine and other resuscitative measures including oxygen, intravenous fluids, antihistamines, corticosteroids, cardiovascular support, and airway management as clinically indicated.
Seroconversion from a negative to a positive direct Coombs' test result has been reported. Drug-induced hemolytic anemia should be considered if anemia develops during or after ceftaroline therapy. Diagnostic studies, including a direct Coombs' test, are recommended. If drug-induced hemolytic anemia is suspected, ceftaroline discontinuation should be considered and supportive care should be administered to the patient (i.e., transfusion) if clinically indicated.
Clostridium difficile associated diarrhea (CDAD) has been reported with almost all antibiotics and may potentially be life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea following cephalosporin therapy. Mild cases generally improve with discontinuation of the drug, while severe cases may require supportive therapy and treatment with an antimicrobial agent effective against C difficile. Hypertoxin producing strains of C difficile cause increased morbidity and mortality; these infections can be resistant to antimicrobial treatment and may necessitate colectomy.
To reduce the development of drug-resistant organisms, antibiotics should only be used for prophylaxis or treatment of infections that are proven or strongly suspected to be due to bacteria.
Safety and efficacy have not been established in pediatric patients (less than 18 years).
Hemodialysis: 200 mg IV, infused over 1 hour, every 12 hours
Because ceftaroline is hemodialyzable, it should be administered after hemodialysis on hemodialysis days.
CAPD: Data not available
Therapy duration should be guided by severity and site of infection and by patient's clinical and bacteriological progress.